◀ Back to PLAU

MMP1 — PLAU

Pathways - manually collected, often from reviews:

• OpenBEL Selventa BEL large corpus: MMP1 → PLAU (increases, PLAU Activity, MMP1 Activity)
  Evidence: The plasmin-plasminogen activator system and matrix metalloproteinases (MMPs) cooperate in this degradation [20]. uPA converts plasminogen into plasmin, a serine protease that degrades fibrin and other matrix proteins, and activate several MMPs, including stromelysin- 1 (MMP-3), collagenase-1 (MMP-1), type IV collagenases (MMP-2 and MMP-9) [21]. FGF1, FGF2, and FGF4 upregulate uPA and MMPs production in endothelial cells.

Text-mined interactions from Literome

Menshikov et al., Biochem J 2002 : In the present study, the role of uPA in regulating matrix metalloproteinase ( MMP ) expression and release by the monocyte cell line THP-1 was investigated
Gillette et al., Tumori 2003 : We detected MMP-7, urokinase plasminogen activator (uPA) and PAI-1 in both Matrigels, TIMP-2 was detected only in regular Matrigel and no MMP-1 or TIMP-1 was detected in either matrix
Quemener et al., Cancer Res 2007 (Breast Neoplasms...) : EMMPRIN expressing cells also exhibited enhanced invasive potential in vitro, and the use of amiloride ( uPA inhibitor ) and marimastat ( MMP inhibitor ) showed that the two proteolytic systems reduced alone and in combination the invasive potential mediated through EMMPRIN
Solberg et al., J Surg Res 2011 (Appendicitis) : The expression and distribution of MMP-1 , -2, and -9, the tissue inhibitor of metalloproteinases type ( TIMP-1 ), plasminogen activator inhibitor type1 ( PAI-1 ), and urokinase plasminogen activator (uPA) were measured by ELISA